24 / 28
Pathology 2018
Research & Reviews: Journal of Medical and Health Sciences
ISSN: 2319-9865
Page 79
October 08-09, 2018
Edinburgh, Scotland
17
th
International Conference on
Pathology & Cancer
Epidemiology
Purpose:
Male breast carcinoma (MBC) is treated similarly to
female breast carcinoma (FBC), and similar survival rates for
both have been assumed. We analyzed prognostic and clinico-
pathologic features of MBC to determine whether MBC subtypes
differ from FBC subtypes.
Methods:
We reviewed data for 172,847 FBC and 1,442 MBC
patients from 2010 to 2012 from the National Cancer Institute
Surveillance, epidemiology, andend resultsdatabase. Carcinomas
were subtyped by hormone receptor (HR) and human epidermal
growth factor 2 (HER2) status as HR+/HER2–, HR+/HER2+, HR–/
HER2+, and HR–/HER2–.
Results:
The overall incidence of MBC in all breast carcinoma
cases was 0.8%. MBC was more frequently HR+/HER2– than FBC
was (78.3% vs. 67.4%) and less frequently HR–/HER2– (2.1% vs
10.9%). More MBC was staged as III or IV (24.9% vs. 17.2%). MBC
had significantly worse overall survival (OS) than FBC (P<0.0001).
After adjustment for age, ethnicity, and tumor grade, stage I and
II MBC had significantly worse OS time than stage-matched FBC
had (P=0.0011 for stage I, P=0.0229 for stage II). When stage- and
subtype-matched patients were compared, MBC had significantly
worse OS than FBC for stage I overall, for sub-stages IA and IIB
HR+/HER2– carcinoma, and for stage III HR+/HER2+ carcinoma.
Furthermore, MBC patients with HR+/HER2– T1aN0 carcinomas
had worse OS than FBC patients had.
Conclusions:
PatientswithMBChaveworse survival than patients
with FBC, especially for early-stage HR+ breast cancers. More
studies are needed to optimize treatment for MBC.
Xli40@emory.eduHormone receptor – positive breast cancer has a worse
prognosis in male than in female patients
Xiaoxian (Bill) Li
Emory University, USA
RRJMHS 2018
Volume: 7